IR

News

[The Bio] How did the frontrunners take the lead?

The effectiveness of mRNA vaccines has been confirmed during the COVID-19 pandemic. Now, mRNA platform technology is being applied to the development of "cancer vaccines," extending its potential beyond prevention to treatment.

Our CEO, Mr. Tae-jin Kang, will be contributing a series of five expert articles to the pharmaceutical and biotechnology media outlet "THEBIO," discussing how this technology is being utilized in the development of cancer vaccines, as well as the current trends and status of the technology.

Through this series, we expect readers to gain insights into the present and future of mRNA cancer vaccine technology.

Have you heard about a biotech company called BioNTech? Part 4 (How did the frontrunners take the lead?) introduces the development schedule of BioNTech's mRNA cancer vaccine, which has gained attention for being the first in the world to develop a COVID-19 vaccine in partnership with Pfizer. For more details, please check the link below.


2024-10-22

[The Bio] Did you know that AI technology is being used in the production of personalized cancer vaccines?

The effectiveness of mRNA vaccines has been confirmed during the COVID-19 pandemic. Now, mRNA platform technology is being applied to the development of "cancer vaccines," extending its potential beyond prevention to treatment.

Our CEO, Mr. Tae-jin Kang, will be contributing a series of five expert articles to the pharmaceutical and biotechnology media outlet "THEBIO," discussing how this technology is being utilized in the development of cancer vaccines, as well as the current trends and status of the technology.

Through this series, we expect readers to gain insights into the present and future of mRNA cancer vaccine technology.

Are you aware that AI technology is essential for the production of personalized cancer vaccines? The Part 3 (Did you know AI technology is used in the production of personalized cancer vaccines?) introduces the process of producing personalized cancer vaccines, which is a representative example of the fusion of AI technology and biotechnology (BT).

2024-10-15

[The Bio] Is defense important in soccer? Or is offense more important?

The effectiveness of mRNA vaccines has been confirmed during the COVID-19 pandemic. Now, mRNA platform technology is being applied to the development of "cancer vaccines," extending its potential beyond prevention to treatment.

Our CEO, Mr. Tae-jin Kang, will be contributing a series of five expert articles to the pharmaceutical and biotechnology media outlet "THEBIO," discussing how this technology is being utilized in the development of cancer vaccines, as well as the current trends and status of the technology.

Through this series, we expect readers to gain insights into the present and future of mRNA cancer vaccine technology.

Part 2 (Is defense important in soccer? Or is offense more important?) discusses which is more critical between preventive vaccines and therapeutic vaccines in 'overcoming and treating cancer'. What do you think is more important? For more details, please check the link below.

2024-10-08

[The Bio] [Cancer Vaccine] Novel Prize Winning 'mRNA Vaccine' Technology... Evolves Again

The effectiveness of mRNA vaccines has been confirmed during the COVID-19 pandemic. Now, mRNA platform technology is being applied to the development of "cancer vaccines," extending its potential beyond prevention to treatment.

Our CEO, Mr. Tae-jin Kang, will be contributing a series of five expert articles to the pharmaceutical and biotechnology media outlet "THEBIO," discussing how this technology is being utilized in the development of cancer vaccines, as well as the current trends and status of the technology.

Through this series, we expect readers to gain insights into the present and future of mRNA cancer vaccine technology.

The first article, titled "Novel Prize Winning 'mRNA Vaccine' Technology... Evolves Again," explains the process by which mRNA vaccine technology has evolved into cancer vaccines. For more detailed information, please refer to the link below.

2024-10-02

[News Medical] Phase 1 trial shows safety and efficacy of personalized vaccine for lymphoplasmacytic lymphoma

The recent Phase 1 clinical trial conducted at City of Hope have shown that a personalized vaccine is safe and effective in treating lymphoplasmacytic lymphoma (LPL). This vaccine is tailored to each patient, helping the immune system to attack cancer cells more effectively. In this small-scale trial (9 patients), promising immune responses were observed with manageable side effects. Researchers are hopeful that this approach will improve outcomes for LPL patients, and further studies are planned to confirm these findings and explore the vaccine's potential in larger populations.

Dr. Larry Kwak, a prominent oncologist and researcher at City of Hope, is leading the development of this personalized cancer vaccine. He also serves as the Scientific Advisor for Renhaim Inc. and his collaboration with this Korean start-up biotech aims to advance innovative cancer therapies using Renhaim's mRNA technology. 

For more details, please refer to the link below.

2024-09-27

[City of Hope] Relapsed Lymphoma Patient Thrives After CAR T Cell Trial

The article highlights the story of a lymphoma patient who experienced a relapse after initial treatments including CD19 CAR-T therapy. Seeking alternative options, the patient participated in a novel CAR T-cell therapy trial at City of Hope. This innovative treatment (BAFFR CAR-T) involved reengineering the patient’s own T-cells to better target cancer cells. After undergoing the trial, the patient achieved a remarkable remission. The article emphasizes the hope that BAFFR CAR T-cell therapy offers for patients with difficult-to-treat lymphomas. It also discusses the ongoing research and advancements in immunotherapy. The patient’s journey showcases resilience and the potential for groundbreaking treatments in oncology. Overall, it illustrates the positive impact of clinical trials on patient outcomes.

 

For more details, please refer to the link below.

2024-09-24

[CBC News] A lymphoma survivor talks about his treatments with CAR T-cell therapy to fight cancer

Howard Chew, lymphoma survivor, underwent a clinical trial of CAR T-cell therapy. At first, it didn’t work, but a second treatment proved successful. Chew tells his story and Elizabeth Budde, M.D., P.H.D., City of Hope hematologist-oncologist, talks about the development of the therapy and its benefits.

 

For more details, please refer to the link below.

2024-09-24

[The Bio] Special Contribution (Topic: CAR-T Treament) ③

CEO of our company, contributed a special project (Topic: CAR-T treatment) consisting of three part to commemorate the 1st anniversary of the founding of the pharmaceutical bio-specialized media "THE BIO."

 

For more details, please refer to the link below.

2024-07-05

[The Bio] Special Contribution (Topic: CAR-T Treatment) ②

CEO of our company, contributed a special project (Topic: CAR-T treatment) consisting of three part to commemorate the 1st anniversary of the founding of the pharmaceutical bio-specialized media "THE BIO."

 

For more details, please refer to the link below.

2024-07-04